The TRAIN-study


Neurofibromatosis type 1 (NF1) is one of the most common neuro-genetic diseases. About half of the patients with NF1 have large bumps known as plexiform neurofibromas. These cause serious cosmetic problems, but also cause disability and severe pain. Until now, surgery is the only treatment option, but this is not always possible. That's why medicines are badly needed. Recent research has shown that individuals with NF1 and a non-operable plexiform neurofibroma benefit from medicinal treatment. As a result of this study, Erasmus MC will conduct a study with trametinib in adult NF1 patients with plexiform neurofibromas that cause complaints.

Click here for English information on about this study (including inclusion and exclusion criteria).

If you have any questions, please contact:

Dr. Walter Taal, neurologist
Sarah van Dijk, nurse specialist

Telephone number: 010-7041415